![]() ![]() Food and Drug Administration (FDA) for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding – to one without it where patients were given 4-Factor Prothrombin Complex Concentrate (4F-PCC), which is only approved for the reversal of warfarin and has no impact on anti-Factor Xa levels. The analysis compared a clinical scenario with Andexxa – the first and only antidote approved by the U.S. "The findings demonstrate that healthcare providers can focus on FDA-approved indications for use, clinical evidence and society guidelines when providing care to patients rather than the cost of treatment." "This model, and the projected cost savings with Andexxa compared to 4F-PCC outlined in our study, is important to share among hospital pharmacists and administrators," said Mr. The data was presented by John Fanikos, B.Pharm., M.B.A., executive director of pharmacy services at Brigham and Women's Hospital, Boston, in a poster session at the Emergencies in Medicine Meeting, which is taking place March 1-6 in Park City, Utah. ® (Nasdaq: PTLA) today announced the presentation of new data demonstrating that using Andexxa ® to treat patients with intracranial hemorrhage (ICH) associated with the oral Factor Xa inhibitors apixaban or rivaroxaban is projected to provide a net reduction in costs to an acute care hospital. SOUTH SAN FRANCISCO, Calif., Ma/PRNewswire/ - Portola Pharmaceuticals, Inc. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |